Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb.
The director of the Biomedical Advanced Research and Development Authority has launched two new funding programs in the past three years.
New outcomes data shows that the firm's test can help clinicians optimize antibiotic prescribing, but investment analysts have had mixed reactions.
For the first time ever, the center is funding the development of diagnostic systems — specifically for the development of three devices to detect the infection.
Based in Warsaw, Poland, the technology was inspired by "ultra-fast" PCR methods from the Wittwer group and Scope plans to launch tests for MRSA and C. diff.
While the news of the BARDA contract drove a surge in T2's stock price, it was last month's NTAP decision that has company officials and analysts encouraged.
New resistance tests for Mycoplasma genitalium and gonorrhea could help stave off superbugs, but guidelines and economic factors may hinder adoption.
The new test uses the number of sequencing reads at specific early and late HPV transcripts as a biomarker for high-grade cytology.
The clearance of the Binx io CT/NG test marks a milestone for the Johns Hopkins University group that funds early-stage development of rapid STI testing.
The company provided updates on its newborn screening testing presence.
The firm provided updates on its bacterial pathogen detection and antimicrobial resistance testing for bacterial isolates and a direct-from-urine test.